Exhibit 99.1

Nasdaq: AEMD www.AethlonMedical.com Corporate Presentation April 2024

FORWARD LOOKING STATEMENTS This investor presentation contains forward - looking statements, as that term is defined in the Private Securities Litigation Ref orm Act of 1995 as contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, a s a mended, which are subject to the “safer harbor” created by those sections. All statements other than statements of historical fact containe d i n this presentation are forward - looking statements, including, without limitation, statements regarding: Aethlon’s ability to enroll patients in Aet hlon’s ongoing and planned clinical trials; Aethlon’s ability to successfully complete Aethlon’s clinical trials and achieve the endpoints for t he trials, or any future clinical trials with Aethlon’s Hemopurifier® or to successfully develop and commercialize the Hemopurifier®; Aethlon’s abilit y t o demonstrate the removal of nanoparticles (NPs), extracellular vesicles (EVs) and their associated cargo with the Hemopurifier®; the poten tia l synergistic use of the Hemopurifier with chemotherapy, immunotherapy and targeted agents; Aethlon’s ability to successfully demonstrate the b ene fit of Aethlon’s Hemopurifier® in the organ transplant setting; and Aethlon’s ability to raise additional capital and to maintain Ae thl on's listing on the Nasdaq Capital Market (Nasdaq); and Aethlon's ability to establish and maintain collaborations. These forward looking statem ent s are subject to a number of risks, uncertainties and assumptions, including, but not limited to: the timing and success of Aethlon's clini cal trials and preclinical research with the Hemopurifier® in the organ transplant setting; Aethlon's ability to enroll patients in Aethlon' s o ngoing and planned clinical trials on a timely basis, or at all; Aethlon's dependence on Aethlon's CROs and other third parties; Aethlon's abili ty to manufacture Aethlon's Hemopurifiers®; Aethlon's ability to obtain regulatory approvals within the timeframes expected, or at all; complic ati ons associated with product development and commercialization activities; the size and growth of the market(s) for the Hemopurifier® and the ra te and degree of market acceptance thereof; Aethlon's ability to raise additional capital; Aethlon's ability to remain listed on Nasdaq; an d A ethlon's ability to attract and retain key management, and members of Aethlon's board of directors. In light of these risks and uncertainties, a nd other risks and uncertainties that are described in the Risk Factors section of Aethlon’s Form 10 - K filed with the Securities and Exchange Commi ssion (SEC) on June 28, 2023, subsequent filings with the SEC on Forms 10 - Q and 8 - K, and other filings that Aethlon makes with the SEC from tim e to time (which are available at http://www.sec.gov), the events and circumstances discussed in such forward - looking statements may not o ccur, and Aethlon’s actual results could differ materially and adversely from those anticipated or implied thereby. Any forward - looking st atements speak only as of the date of this presentation and are based on information available to Aethlon as of the date of this presentatio n, and Aethlon undertakes no duty to update such information except as required under applicable law. All third - party brand names and logos ap pearing in this presentation are trademarks or registered trademarks of their respective holders. Any such appearance does not necessar ily imply any affiliation with or endorsement of the Company. 2 Investment Highlights 3 • Developing novel, patented Hemopurifier blood purification device • Early clinical trials have demonstrated virus and EV (extracellular vesicles, which include exosomes) clearance both in vitro an d in patients • The FDA has designated the Hemopurifier® as a “Breakthrough Device” • The treatment of individuals with advanced or metastatic cancer • The treatment of life - threatening viruses that are not addressed with approved therapies • Focused on multiple therapeutic targets in cancer, viral disease and organ transplantation • Solid tumors failing anti - PD1 • COVID - 19 • Proof - of - concept studies underway in organ transplantation • U.S. and international clinical trials • Planned oncology trials in Australia and in India • Open COVID - 19 trial in India • Broad patent portfolio • Experienced management team

The Aethlon Hemopurifier® FDA Designated “Breakthrough Device” In Viral And Oncology Indications • Safely administered in 164 Hemopurifier sessions in 38 patients 1 • Proprietary, patented technology • Has demonstrated clearance of life - threatening viruses • Designed to clear tumor - derived EVs, and their associated cargo (Oncology) 4 1.

Aethlon clinical safety database The Hemopurifier ® Is Designed To Capture Viruses And Extracellular Vesicles From A Patient’s Blood Via Extracorporeal Circuit Potential Therapeutic Applications: • Cancer • Life - threatening viral infections • Organ Transplantation 5 Pipeline Targeting Multiple Indications Pre - Clinical Early Feasibility Study Indication 6 Kidney Transplantation Organ Transplantation Pre - clinical Translational Activities Solid Tumors failing anti - PD - 1 Expected to begin in Australia and India pending supporting data Oncology HCV HIV India COVID - 19 Ongoing Completed Single patient case study, Completed Emergency Use COVID - 19, Ebola Viral Infections

The Rationale Exists For The Removal Of Tumor - derived Extracellular Vesicles By Aethlon’s Hemopurifier ® To Treat Cancer Extracellular Vesicles (EVs) are small membrane - bound particles that serve as key mediators of cell - cell communication. They carry lipids, proteins, and nucleic acids, and are released by most cell types, including tumor cells. Specifically, EVs and their cargo : • Have been shown to contribute to the spread of cancer (metastases) 1 • Play a role in immune system evasion by the tumor 1 • Facilitate chemotherapy resistance 1 • Interfere with antibody - based treatments (e.g., PD - 1 antibody therapies such as Keytruda® and Opdivo ®) 2 We believe the removal of harmful EVs and their associated cargo may enhance existing cancer treatments The Hemopurifier ® has demonstrated clearance of EVs in vitro and in patients 3 7 1. Zhang L, Yu D. Biochim Biophys Acta Rev Cancer. 2019 Apr;1871(2):455 - 468. 2. Rasihashemi SZ, Gavgani ER, Majidazar R, et al . J Cell Physiol 2021:1 - 13. 3. Amundson DE, Shah US, de Necochea - Campion R, et al Front Med (Lausanne). 2021 Oct 8;8:744141.

In Vitro Removal Of Cancer - Derived EVs from Buffer Has Been Demonstrated 1 • Tumor derived EVs were isolated from cancer patient plasma and suspended in buffer • Samples were circulated over a scaled - down version of the Hemopurifier ® • EV counts were quantified before and after passage over the scaled down device • The scaled down Hemopurifier was effective for clearing 92 - 99% of EVs suspended in buffer • Demonstrated capture of EVs from diverse tumor types including head and neck cancer, melanoma , ovarian cancer, esophageal cancer and breast cancer Aethlon is exploring the therapeutic potential of removing tumor - derived EVs in cancer patients with the Hemopurifier ® 1. Marleau AM, Jacobs MT, Gruber N, et al . Cancer Res 2020;80 (16_Supplement):4509. 8 Clinical Development Plans Underway In Oncology • A n ew safety phase clinical trial in oncology is planned to include multiple tumor types, as well as dosing intervals, to help direct the development of Aethlon’s Hemopurifier ® as a treatment option in oncology • Aethlon h as contracted with North American Science Associates, LLC (NAMSA), a major global contract research organization (CRO), to direct the planned oncology study in Australia and the U.S. • Aethlon has contracted with Qualtran LLC, a CRO focused on India, to direct the planned oncology trial in India • Interested sites have been identified in Australia and India with next step being Ethics Committee approvals in those countries • Aethlon needs to complete binding studies prior to the interested sites asking for Ethics Committee approvals 9

Recent Scientific & Clinical Literature Provides A Rationale For Hemopurifier Treatment In Severe COVID – 19 Infections • COVID viremia is detected in ~34% of patients and is associated with severity, requirement for ICU stay, development of multi - organ failure and poor outcomes 1 • Direct viral injury to non - pulmonary organs has been noted in a COVID post - mortem study 2 • Viremia in COVID is associated with immune dysregulation , endothelial injury , coagulopathy and complement activation 3 • EVs and exosomal miRNAs may play a role in the spread of infection as well as ongoing inflammation , development of coagulopathy and lung injury 4 • Aethlon’s proprietary Galanthus nivalis agglutinin (GNA) affinity resin has been shown to bind multiple clinically relevant SARS - CoV - 2 variants 5 Demonstrated removal of SARS - CoV - 2, EVs and miRNAs in patients treated with the Hemopurifier ® 10 1.Tang K, Wu L, Luo Y, Gong B.. J Med Virol . 2021 May;93(5):3165 - 3175. 2. Deinhardt - Emmer S, Wittschieber D, et al . Elife . 2021 Mar 30;10:e60361. 3. Bermejo - Martin JF, González - Rivera M, et al. Crit Care. 2020 Dec 14;24(1):691. 4. Barberis E, Vanella VV, Falasca M, et al. Front Mol Biosci . 2021 Feb 22;8:632290. 5. Gooldy M, Roux CM, LaRosa SP, et al. PLoS One. 2022 Jul 28;17(7):e0272377.

In Vitro Removal of Clinically Relevant SARS - CoV - 2 Variants by an Affinity Resin Bearing GNA 1 Has Been Demonstrated 11 » Seven SARS - CoV2 variants ( 10 4 PFU/mL) in P hosphate Buffered Salin e ( PBS) buffer passed 3X over column of GNA affinity resin (1g) 1. Gooldy M, Roux CM, LaRosa SP, et al . PLoS One. 2022 Jul 28;17(7):e0272377. Table 2. Average Column Capture Efficiency for SARS - CoV - 2 Variants Capture Efficiency (%) Variant ID 69.3 ± 11.4 NR 54009 (South Africa) 69.8 ± 4.7 NR 54000 (UK) 89.0 ± 3.7 NR 54982 (Brazil) 78.8 ± 1.9 NR 55672 (B.1.672 Delta) 70.5 ± 3.6 NR 55657 (Lambda) 53.2 ± 11.6 NR 55691 (AY.1 Delta) 89.9 ± 2.1 NR 56461 (Omicron)

12 Evidence of In Vivo Removal of SARS - CoV - 2 1 Viremic Emergency Use patient in the ICU with critical disease • Request received from Hoag Newport Beach Hospital (Usman Shah, M.D.) on 14 JAN 2021 • 67 - year - old male with PMH of Tetralogy of Fallot, CAD and DM admitted on 6 JAN 2021 with hypoxia and SOB • Confirmed diagnosis of COVID - 19 by PCR • Progressed to multi - organ system failure (CV, Respiratory and Kidney) despite Remdesivir, Dexamethasone, Convalescent plasma, Baricitinib and full dose anticoagulation • Required two vasopressors to maintain blood pressure • On mechanical ventilation in the prone position with FIO2 of 90% and PEEP on 8 • On CRRT for renal replacement therapy • SOFA score 13 - Predicted risk of mortality ~80% • Reduced patient’s viral load by 58.4% during the treatment Decrease in COVID - 19 viral load following Hemopurifier ® treatment; Hemopurifier ® treatment was well tolerated 1. Amundson DE, Shah US, de Necochea - Campion R, et al Front Med (Lausanne). 2021 Oct 8;8:744141.

13 Evidence of SARS - CoV - 2 Capture and Clearance by Hemopurifier ® 1 • Independent Physician Assessment confirmed request for emergency use 14 JAN 2021 • IRB approval and Signed Inform Consent obtained (14 JAN 2021) • Patient underwent 6 - hour 15 minute Hemopurifier session between (0645 - 1300 hours) • No cartridge evidence of hemolysis or thrombosis • Patient had fluctuating BP and required increased O2 during session • Patient Removed from Hemopurifier ® without incident • Blood pressure noted to start dropping after new CRRT circuit placed with precipitous drop in Oxygenation and BP at 1400 hours • Patient developed refractory shock and hypoxia and expired due to a PEA arrest at 1549 VIRAL COPIES NORMALIZED TO RNase P Plasma (Copies/mL) 1558.6 Pre - HP plasma 648.1 Post - HP plasma 58% reduction of SARS - CoV - 2 plasma viral load 1. Amundson DE, Shah US, de Necochea - Campion R, et al Front Med (Lausanne). 2021 Oct 8;8:744141.

Demonstrated Reduction Of Total EVs And Harmful Cargo In An Emergency Use COVID - 19 Patient Treated With Hemopurifier ® 1 Total EV’s and Exosomal 2 miRNA over time: 14 COVID - 19 plasma viral load was undetectable at onset of Hemopurifier treatment 1. Amundson DE, Shah US, de Necochea - Campion R, et al Front Med (Lausanne). 2021 Oct 8;8:744141. 2. Exosomes are a subpopulation of extracellular vesicles, nanosized particles, lipid bilayer - enclosed, naturally secreted from cells after the fusion of intracellular Multivesicular bodies with the plasma membrane. Di Bella MA. Biology 2022 Jun; 11(6): 804. miR - 424 is associated with COVID - associated coagulopathy (excessive blood clotting) miR - 16 is associated with acute lung injury 0 2E+11 4E+11 6E+11 8E+11 1E+12 1.2E+12 1.4E+12 0 0.1 0.2 0.3 0.4 0.5 0.6 Day1-Pre Day1-Post Day2-Pre Day2-Post Day3-Pre Day3-Post Day4-Pre Day4-Post Day5-Pre Day5-Post Day6-Pre Day6-Post Day7-Pre Day7-Post Day8-Pre Day8-Post Exosomes/ml Plasma Normalized Exosome miRNA/ml plasma Exosomes and miR - 424 miR-424 Exosomes 0 2E+11 4E+11 6E+11 8E+11 1E+12 1.2E+12 1.4E+12 0 0.02 0.04 0.06 0.08 0.1 0.12 0.14 Day1-Pre Day1-Post Day2-Pre Day2-Post Day3-Pre Day3-Post Day4-Pre Day4-Post Day5-Pre Day5-Post Day6-Pre Day6-Post Day7-Pre Day7-Post Day8-Pre Day8-Post Exosomes/ml Plasma Normalized Exosome miRNA/ml Plasma Exosomes and miR - 16 miR-16 Exosomes COVID - 19 India Trial U pdate: T reatment Of SARS - CoV - 2 Infection In H umans W ith Hemopurifier ® D evice • Regulatory agency in India approved the use of Hemopurifier ® devices for clinical trial use • Studying ICU patients with severe or life - threatening disease • Designed to include up to 15 patients at up to three centers • One patient enrolled and treated • Added a second hospital site in India in 2023 • Trial remains open for enrollment 15

Hemopurifier ® Clinical Development Summary Oncology • Safety, feasibility and dose finding study in solid tumors failing anti - PD - 1 antibodies • Planned to be initiated first in Australia and India and then in the United States Viral Infections • Clinical trial of Hemopurifier ® in severe COVID - 19 infection • Currently underway in India 16 In vitro data highlights potential Hemopurifier® applications in organ transplantation 1 • Recovered deceased donor kidneys are typically placed on machine perfusion for preservation and transport to the transplant recipient • In vitro data using the Hemopurifier to filter kidney perfusates removes noxious agents 1 • Extracellular vesicles 2 and harmful cargos • Virus and viral particles (e.g., HCV) • RNA molecules • Cytokines, chemokines and other inflammatory molecules • These early findings suggest that Hemopurifier filtration of organ perfusates may provide benefits • Improved graft function / reduction in graft rejections • Maintain or improve organ viability prior to transplantation • Potential to reduce the number of kidneys rejected for transplant • Additional preclinical experiments are planned and underway 17 1. Aethlon internal research, unpublished data 2. Exosomes are a subpopulation of extracellular vesicles, nanosized particles, lipid bilayer - enclosed, naturally secreted from cells after the fusion of intracellular Multivesicular bodies with the plasma membrane. Di Bella MA. Biology 2022 Jun; 11(6): 804.

Hemopurifier® filtration of deceased donor kidneys recovered for transplantation represents an exciting opportunity • In the United States in 2023, approximately 30,000 kidneys were recovered from 15,417 deceased donors for transplantation 1 • Number of deceased donor kidneys is expected to grow to approximately 60,000 by 2034 1 • Hypothermic machine perfusion (HMP) has been shown to reduce delayed graft function and improve one - year graft survival compared to cold static storage 2 • HMP continuously circulates a preservation solution through the organ at temperatures between 1 and 10 degrees C • Historically, static cold storage in liquid ice was the predominant preservation technique • Today, most recovered deceased donor kidneys are placed on hypothermic machine perfusion (HMP) for organ preservation and transportation to recipients • Hemopurifier use during HMP may have the potential to provide additional benefits • e.g., greater utilization of recovered kidneys, improvements in delayed graft function in transplant recipients, etc. • Clinical studies will be required to show any potential benefits 18 1. Organ Procurement & Transplantation Network data reported for 2023; annual donor growth rate of 6% 2016 - 2023; assumed 2 kidne ys were recovered per deceased donor 2. Jiao, B, et al. PL0S One.

2023 Dec 10;8(12):e81826 Aethlon’s patent portfolio provides protection until as early as 2029 (issued patents) and late as 2042 (if pending applications grant) United States • Issued Patents: • 3 US patents issued covering extracorporeal removal of microvesicular particles, patent protection until 2029 • 2 US patents issued covering removal of viruses, patent protection until 2025 • Patent Applications: • 2 US applications pending covering removal of Covid - 19 viral particles and associated exosomes • Patent protection until 2042 if granted International • Issued Patents: • 24 foreign patents covering exosomes and microvesicular particle removal • Patent protection extending to 2031 in Germany, France, Great Britain, and Spain • Patent protection extending to 2027 in Canada, Switzerland, Italy, Netherlands, Sweden, Hong Kong, Demark and Ireland • Patent Applications: • 12 pending foreign applications directed to removal of Covid - 19 viral particles and associated exosomes, patent protection to 2042 if granted • 1 pending international application directed to removal of exosomes, ectosomes, miRNAs, circulating nucleic acids, and viral particles associated with tissues selected for transplantation, patent protection to 2044 if granted 19 Key Financial Highlights • Approximately $8.0 million in cash as of December 31, 2023 • No debt on balance sheet • Approximately 2.6 million shares outstanding as of April 5, 2024 • Market capitalization of $4.5 million as of April 5, 2024 • Trading on Nasdaq under the ticker “AEMD” 20

Senior Management Team Has Extensive Experience With Both Medical Devices And Therapeutics James B. Frakes, MBA, Interim CEO & Chief Financial Officer • Over 30 years public company CFO experience • Investment banking & venture capital Guy Cipriani, MBA, Chief Operating Officer • 20 years transactional and operational experience with public and private biotech & device companies Steven P. LaRosa, MD, Chief Medical Officer • 25 years clinical and research experience in i nfectious diseases, critical care, coagulation, inflammation, and extracorporeal devices Lee Arnold, PhD, Chief Scientific Officer • Over 30 years experience in molecularly - targeted drug discovery .

• 94 published patents and applications, and more than 39 peer - reviewed publications Background Experience 21 11555 Sorrento Valley Road, Suite 203 San Diego, California 92121 619.941.0360 Nasdaq: AEMD www.AethlonMedical.com This presentation may contain predictions, estimates, and other forward looking statements that involve risks and uncertainti es, including: whether and when our products may be successfully developed and introduced; the anticipated market acceptance of the Aethlon Hemopurifier®; and the likelihood of regulatory or manufacturing delays. These risks and uncertainties are detailed in our S EC filings, which are accessible at www.sec.gov or on our website, www.AethlonMedical.com 22 Contact Information